An new experimental regimen of once-weekly breast irradiation following lumpectomy provides more convenience to patients at a lower cost, results in better completion rates of prescribed radiation treatment. In addition, the treatment produces cosmetic outcomes comparable to the current standard of daily radiation.
This conclusion is based on interim results of the 5-year Phase II clinical trial using the experimental were presented at 
the Breast Cancer Symposium 2014being held September 4 – 6, 2014, in San Francisco, California by Anthony E. Dragun, M.D., vice chair and associate professor of radiation oncology at the University of Louisville in Kentucky, USA.
Only US Site
Dragun, a radiation oncologist with University of Louisville Physicians, launched the trial three years ago at UofL?s James Graham Brown Cancer Center, a part of KentuckyOne Health and the only site offering the experimental regimen in the United States. A second KentuckyOne Health site is being planned and is expected to begin enrolling patients this autumn.
…this once-weekly regimen of breast irradiation following lumpectomy… will become a standard option in the next decade…
Alternative therapy
Reviewing data from Europe, in particular the United Kingdom, Dragun found an alternative to the currently standard daily radiation treatments prescribed to patients after a lumpectomy. Physicians in the United Kingdom and other European countries were reporting excellent results with a regimen of radiation administered once-weekly.
?Instead of daily treatments for 25-30 days, five to six treatments administered once each week were being used,? Dragun said. ?I thought this regimen would give our patients here in Kentucky a great deal of access and choice, so we developed the trial and launched it in 2011.?
Approximately 150 female patients have been enrolled in the trial thus far. Patients undergoing a lumpectomy following diagnosis of breast cancer are given a choice of the current standard of daily radiation treatments or the option to enroll in the trial and receive treatment one time per week.
“The radiation dosing has been calibrated to compensate for the change in how the treatments are administered, but no adverse effects have been seen”, Dragun explained. ?The outcomes with once-weekly treatments are absolutely in line with what we see in daily breast irradiation,? he said. ?The standard of care is maintained.?
More women complete treatment
Giving women the choice of how their treatment is administered means more women complete their treatment, he said. ?Finding time for daily treatments for 6 weeks or more just isn?t possible for many women,? Dragun noted. ?Scheduling once-weekly treatments is much easier to fit into the busy lives our patients lead.
?We also see many patients who depend on public transportation or live in rural areas that are 30 miles or more from our center, and they have told us that they would not have been able to complete a traditional course of daily radiation treatment. Their only alternative would be a mastectomy,? he said.
Lower overall costs
Because radiation treatment is reimbursed on a per-treatment basis, Dragun explained that the overall cost is lowered. ?We have reduced the number of treatments to about one-fourth to one-third of what the current daily treatment regimen is,? he said. ?Medicare reimburses radiation costs on a per-treatment basis, and most private insurers do likewise.
?This means we?ve been able to reduce the cost by 50 – 60% without jeopardizing the quality of care.?
Dragun plans to enroll another 50 patients at the Louisville site and 30 at the future trial site. After the completion of this trial, he intends to expand into a multi-center Phase III trial at facilities in other states.
?We believe the once-weekly regimen such as this will become a standard option in the next decade,? he said.
For more information:
[1] Dragun AE, Riley EC, Quillo AR, Barry PN, Hunter AM, Rajeurs AA, Roberts T, Rai S, et al. A phase II trial of once-weekly hypofractionated breast irradiation: Interim analysis of cosmetic outcome and quality of life. General Poster Session A: Local/Regional Therapy, Survivorship, and Health Policy. J Clin Oncol 32, 2014 (suppl 26; abstr 67)[Abstract]
Photo: Anthony E. Dragun, MD. Photo Courtesy: University of Louisville, Kentucky, USA.
Copyright ? 2014 Sunvalley Communication. All rights reserved. Republication or redistribution of Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of Sunvalley Communication. Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco’Zine and Oncozine are registered trademarks and trademarks of Sunvalley Communication around the world.
